| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
ACTH receptor (adrenocorticotropic hormone receptor / melanocortin 2 receptor, MC2R). ACTH 11-24 is an antagonist of the ACTH receptor.
|
|---|---|
| ln Vitro |
Freshly distributed or grown beef adrenocortical cells respond to ACTH (11-24) by secreting cortisol below the minimum threshold [1].
ACTH 11-24 is an adrenocorticotropic hormone (ACTH) receptor antagonist. It is a fragment of ACTH that induces cortisol release. ACTH (11-24) has been identified as a competitive antagonist of ACTH (1-39) and ACTH (1-10) in isolated adrenal cells. |
| ln Vivo |
Fighting behavior and circulating plasma corticosterone levels are slightly impacted by ACTH (11-24) [2].
No specific in vivo activity data is available for ACTH 11-24. As an ACTH receptor antagonist, it can be used in research on the central nervous system. Its ability to induce cortisol release suggests potential for in vivo studies of the hypothalamic-pituitary-adrenal axis. |
| Enzyme Assay |
In vitro receptor binding assays for ACTH 11-24 involve measuring its affinity for the ACTH receptor (MC2R) using radioligand displacement or functional assays (e.g., cAMP production) in cells expressing the receptor. Competitive antagonism of ACTH (1-39) and ACTH (1-10) can be assessed in isolated adrenal cells.
|
| Cell Assay |
The in vitro cellular activity of ACTH 11-24 is evaluated in adrenal cells expressing the ACTH receptor. Cells are treated with ACTH and the compound, and cortisol production or cAMP levels are measured. The compound's ability to antagonize ACTH-induced signaling is assessed.
|
| Animal Protocol |
No specific in vivo animal experimental protocols are available for ACTH 11-24. For studying ACTH receptor antagonism, the compound could be administered to rodent models via injection, and endpoints would include cortisol levels, stress responses, and HPA axis function.
|
| ADME/Pharmacokinetics |
ACTH 11-24 has a molecular formula of C77H134N24O16 and a molecular weight of 1652.04. It is a peptide fragment of adrenocorticotropic hormone. Sequence: ACTH (11-24).
|
| Toxicity/Toxicokinetics |
No specific toxicological data is available for ACTH 11-24. As a research peptide intended for laboratory use, standard safety precautions should be observed.
|
| References | |
| Additional Infomation |
ACTH 11-24 is an adrenocorticotropic hormone (ACTH) receptor antagonist and a fragment of ACTH that induces cortisol release. It has been identified as a competitive antagonist of ACTH (1-39) and ACTH (1-10) in isolated adrenal cells. It is not approved for clinical use.
|
| Molecular Formula |
C77H134N24O16
|
|---|---|
| Molecular Weight |
1652.03906
|
| Exact Mass |
1651.04
|
| CAS # |
4237-93-8
|
| Related CAS # |
ACTH (11-24) (acetate)
|
| PubChem CID |
3037130
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.81
|
| Hydrogen Bond Donor Count |
21
|
| Hydrogen Bond Acceptor Count |
23
|
| Rotatable Bond Count |
53
|
| Heavy Atom Count |
117
|
| Complexity |
3300
|
| Defined Atom Stereocenter Count |
13
|
| SMILES |
CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N3CCC[C@H]3C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)N
|
| InChi Key |
WNXWTCYVIHOQAJ-IOSGZJLWSA-N
|
| InChi Code |
InChI=1S/C77H134N24O16/c1-44(2)60(97-67(108)56-26-17-39-99(56)72(113)49(82)20-7-11-33-78)69(110)89-43-59(103)90-50(21-8-12-34-79)63(104)91-51(22-9-13-35-80)64(105)92-53(24-15-37-87-76(83)84)65(106)94-54(25-16-38-88-77(85)86)73(114)100-40-18-27-57(100)68(109)98-62(46(5)6)70(111)93-52(23-10-14-36-81)66(107)96-61(45(3)4)71(112)95-55(42-47-29-31-48(102)32-30-47)74(115)101-41-19-28-58(101)75(116)117/h29-32,44-46,49-58,60-62,102H,7-28,33-43,78-82H2,1-6H3,(H,89,110)(H,90,103)(H,91,104)(H,92,105)(H,93,111)(H,94,106)(H,95,112)(H,96,107)(H,97,108)(H,98,109)(H,116,117)(H4,83,84,87)(H4,85,86,88)/t49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,60-,61-,62-/m0/s1
|
| Chemical Name |
(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~60.53 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6053 mL | 3.0266 mL | 6.0531 mL | |
| 5 mM | 0.1211 mL | 0.6053 mL | 1.2106 mL | |
| 10 mM | 0.0605 mL | 0.3027 mL | 0.6053 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
